

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM472791

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ROYAL BANK OF CANADA, as collateral agent		05/04/2018	Corporation: CANADA
RECEIVING PARTY DATA			
Name:	IMPAX LABORATORIES, INC.		
Street Address:	2 WALNUT GROVE DRIVE, SUITE 190		
City:	HORSHAM		
State/Country:	PENNSYLVANIA		
Postal Code:	19044		
Entity Type:	Corporation: DELAWARE		
Name:	TOWER HOLDINGS, INC.		
Street Address:	2 WALNUT GROVE DRIVE, SUITE 190		
City:	HORSHAM		
State/Country:	PENNSYLVANIA		
Postal Code:	19044		
Entity Type:	Corporation: DELAWARE		
Name:	LINEAGE THERAPEUTICS INC.		
Street Address:	2 WALNUT GROVE DRIVE, SUITE 190		
City:	HORSHAM		
State/Country:	PENNSYLVANIA		
Postal Code:	19044		
Entity Type:	Corporation: DELAWARE		
Name:	COREPHARMA, L.L.C.		
Street Address:	2 WALNUT GROVE DRIVE, SUITE 190		
City:	HORSHAM		
State/Country:	PENNSYLVANIA		
Postal Code:	19044		
Entity Type:	Limited Liability Company: NEW JERSEY		
Name:	AMEDRA PHARMACEUTICALS LLC		
Street Address:	2 WALNUT GROVE DRIVE, SUITE 190		
City:	HORSHAM		

CH \$365.00 3933211

State/Country:	PENNSYLVANIA
Postal Code:	19044
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 14

Property Type	Number	Word Mark
Registration Number:	3933211	GLOBAL
Registration Number:	3778453	ELADUR
Registration Number:	4724116	RYTARY
Registration Number:	3849981	COREPHARMA
Registration Number:	3930148	ISODITRATE
Registration Number:	4013212	AMEDRA
Registration Number:	1177791	DEXEDRINE
Registration Number:	3797506	ADRENACLICK
Registration Number:	3101978	TWINJECT
Registration Number:	3449047	TWINJECT AUTO-INJECTOR
Registration Number:	2992781	TWINJECT
Registration Number:	4503141	LINEAGE THERAPEUTICS
Registration Number:	4503142	LINEAGE THERAPEUTICS
Registration Number:	4862811	NUMIENT

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-318-6532
Email: alanagramer@paulhastings.com
Correspondent Name: Alana Gramer
Address Line 1: c/o Paul Hastings LLP
Address Line 2: 200 Park Avenue, 28th Floor
Address Line 4: New York, NEW YORK 10166

NAME OF SUBMITTER:	ALANA GRAMER
SIGNATURE:	/s/ AG
DATE SIGNED:	05/04/2018

Total Attachments: 4

source=Trademark Release 1#page1.tif
source=Trademark Release 1#page2.tif
source=Trademark Release 1#page3.tif
source=Trademark Release 1#page4.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This **RELEASE OF SECURITY INTEREST IN TRADEMARKS** (this "Release") is dated as of May 4, 2018 and delivered by Royal Bank of Canada, in its capacity as Collateral Agent (in such capacity, the "Collateral Agent"), in favor of the Grantors. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Trademark Security Agreement (as defined below) and if not defined therein, then the meanings given in the Security Agreement (as defined below) or the Credit Agreement (as defined below), as the case may be.

WHEREAS, pursuant to that certain Credit Agreement dated as of August 4, 2015 (as amended, restated, amended and restated, modified or supplemented from time to time, the "Credit Agreement"), each Grantor and the Collateral Agent entered into that certain Security Agreement dated as of August 4, 2015 (as amended, restated, amended and restated, modified or supplemented from time to time, the "Security Agreement") and that certain Trademark Security Agreement, dated as of August 4, 2015 (as amended, restated, amended and restated, modified or supplemented from time to time, the "Trademark Security Agreement");

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on August 5, 2015 at Reel/Frame 5593/0016.

WHEREAS, pursuant to the Security Agreement, each Grantor granted to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, including in all of such Grantor's right, title and interest in, to and under the Trademarks set forth on Schedule A attached hereto (collectively, the "Trademark Collateral").

WHEREAS, the Collateral Agent acknowledges the full payment and performance of the Obligations, and as a result desires to terminate and release the security interest in the Trademark Collateral.

NOW, THEREFORE, for and in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent, on behalf of itself and the Secured Parties, hereby (i) terminates, cancels, releases and forever discharges the security interest in the Trademark Collateral, (ii) terminates the Trademark Security Agreement, and (iii) retransfers and reassigns to each Grantor, as applicable and without representation or warranty of any kind, express or implied, free and clear of any claims by the Collateral Agent, all right, title or interest of the Collateral Agent in, to or under the Trademark Collateral of such Grantor.

The Collateral Agent hereby requests that the Commissioner for Trademarks record this Release.

This Release shall be governed by and construed in accordance with the laws of the State of New York.

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed by its duly authorized signatory effective as of the date first above written.

ROYAL BANK OF CANADA,
as Collateral Agent

By: 

Name:

Title: Susan Khokher
Manager, Agency

[Signature Page to Trademark Release]

TRADEMARK
REEL: 006382 FRAME: 0842

SCHEDULE A

UNITED STATES TRADEMARK REGISTRATIONS AND APPLICATIONS

Owner	MARK	SERIAL NO. / REG. NO.	APP DATE / REG. DATE
Impax Laboratories, Inc.	GLOBAL (w/ logo)	US Reg. No. 3,933,211	March 22, 2011
Impax Laboratories, Inc.	ELADUR	US Reg. No. 3,778,453	April 20, 2010
Impax Laboratories, Inc.	RYTARY	US Reg. No. 4,724,116	April 21, 2015
CorePharma, L.L.C.	Corepharma	US Reg. No. 3,849,981	September 21, 2010
CorePharma, L.L.C.	Isoditrate	US Reg. No. 3,930,148	March 8, 2011
Amedra Pharmaceuticals LLC	Amedra	US Reg. No. 4,013,212	August 16, 2011
Amedra Pharmaceuticals LLC	Dexedrine	US Reg. No. 1,177,791	November 17, 1981
Lineage Therapeutics Inc.	Adrenaclick	US Reg. No. 3,797,506	June 1, 2010
Lineage Therapeutics Inc.	Twinject	US Reg. No. 3,101,978	June 6, 2006
Lineage Therapeutics Inc.	Twinject Auto-injector	US Reg. No. 3,449,047	June 17, 2008
Lineage Therapeutics Inc.	Twinject	US Reg. No. 2,992,781	September 6, 2005
Lineage Therapeutics Inc.	Lineage Therapeutics	US Reg. No. 4,503,141	March 25, 2014

Lineage Therapeutics Inc.	Lineage Therapeutics	US Reg. No. 4,503,142	March 25, 2014
Impax Laboratories, Inc.	NUMIENT	Pending (Appl. No. 86/598,890)	April 15, 2015